APSR2026-150

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP10-002
P02
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1211076-46904-Poster_433504.pdf
Format: PDF Only
07. COPD
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Toshiya Inui * Gifu University Graduate School of Medicine Department of Respirology Gifu Japan Chuno Kosei Hospital Department of Respirology Seki Japan
Takuya Kanemaki - Chuno Kosei Hospital Department of Respirology Seki Japan
Yasuhiro Yamauchi - Chuno Kosei Hospital Department of Respirology Seki Japan
Tsunenori Hiraoka - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan
Akihiro Tsukamoto - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan
Masachika Fukui - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan
Yu Kitamura - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan
Daisuke Kawae - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan Chuno Kosei Hospital Department of Respirology Seki Japan
Yuka Sasaki - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan
Komei Yanase - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan
Junki Endo - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan
Toshihiro Asai - Chuno Kosei Hospital Department of Respirology Seki Japan
Yasushi Ohno - Chuno Kosei Hospital Department of Respirology Seki Japan
Hiroyuki Okura - Gifu University Graduate School of Medicine Department of Cardiology Gifu Japan
Yukari Tsubata - Gifu University Graduate School of Medicine Department of Respirology Gifu Japan
Presenting Author Details
Toshiya
Inui
raicho_seven@yahoo.co.jp
+819080776913
41-50
Japan
Original Research
Investigation of Serum Alpha-1 Antitrypsin as a Neutrophilic Biomarker in Chronic Obstructive Pulmonary Disease and Asthma
Maximum 25 words
Abstract Content
Chronic obstructive pulmonary disease (COPD) is typically characterized by neutrophilic airway inflammation, whereas asthma is predominantly associated with eosinophilic inflammation. However, overlapping inflammatory patterns may occur, with eosinophilic inflammation observed in COPD and neutrophilic inflammation present in asthma, which can make clinical differentiation challenging. Unlike eosinophilic biomarkers, simple and clinically practical biomarkers reflecting neutrophilic airway inflammation remain limited. Alpha-1 antitrypsin (AAT), a major circulating inhibitor of neutrophil elastase and a positive acute-phase reactant, may reflect neutrophilic inflammatory activity. This study evaluated the diagnostic performance and clinical relevance of serum AAT in COPD and asthma.
We retrospectively analyzed clinically stable patients who underwent spirometry and serum AAT measurement by nephelometry between August 2021 and December 2024. The study included 35 patients with COPD, 24 with asthma, and 21 with asthma and COPD overlap (ACO), diagnosed according to the Japanese Respiratory Society 2018 criteria. Differences among groups were assessed using the Kruskal–Wallis test with Dunn’s post hoc correction. Clinical correlations were evaluated using Spearman’s rank correlation coefficient.
Serum AAT levels differed significantly among the three groups (p = 0.0001). Post hoc analysis revealed significantly higher AAT levels in COPD compared with asthma (adjusted p < 0.0001). AAT levels in ACO did not differ significantly from asthma (adjusted p = 0.3796) and showed a trend toward lower levels compared with COPD (adjusted p = 0.0529). In COPD patients, AAT correlated positively with COPD Assessment Test (CAT) scores (Spearman’s rho = 0.4616, p = 0.0052). No significant correlations were observed between AAT and forced expiratory volume in one second (FEV1), FEV1/forced vital capacity (FVC), or vital capacity (VC). Receiver operating characteristic analysis for discriminating COPD from asthma yielded an area under the curve of 0.8125 (95% confidence interval 0.6959–0.9291, p < 0.0001). The optimal cutoff was approximately 150 mg/dL (sensitivity 77%, specificity 79%).
Serum AAT may serve as a useful biomarker for differentiating COPD from asthma and for assessing symptomatic severity in COPD, reflecting neutrophilic airway inflammation.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
alpha-1 antitrypsin, neutrophilic airway inflammation, chronic obstructive pulmonary disease
maximum 3 keywords and no abbreviations, separated by commas
The author declares no conflict of interest.
330